2023
DOI: 10.1007/s00467-023-06195-3
|View full text |Cite
|
Sign up to set email alerts
|

Safety of BNT162b2 mRNA COVID-19 vaccine in children with chronic kidney disease: a national population study from South Korea

Young June Choe,
Yo-Han Ahn,
Eunsun Gwak
et al.

Abstract: BackgroundIn South Korea, COVID-19 vaccination has been recommended to children since October 2021, targeting all teenagers aged 12-15 years, with emphasis on high-risk group including chronic kidney disease (CKD) pediatric patients. In this study, we aimed to assess the rate of adverse events following COVID-19 vaccination in children with CKD in South Korea, using national cohort data. MethodsWe retrieved the Korea Disease Control and Prevention Agency-COVID19-National Health Insurance Service (K-COV-N) coho… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 16 publications
0
1
0
Order By: Relevance
“…The risk of purpura, hemorrhagic conditions, or myocarditis/pericarditis was not higher in the vaccinated patients than in the unvaccinated patients. Guillain-Barre syndrome, Kawasaki disease/ MIS-C, and anaphylaxis or anaphylactic shock were not observed in any patient [26]. An important limitation of that study was that only severe adverse effects were screened with the help of the International Classification of Disease codes, and the effects of the vaccine, such as exacerbation of immune-mediated disease, progression of CKD stage, and rejection in transplant patients, were not evaluated.…”
Section: Discussionmentioning
confidence: 99%
“…The risk of purpura, hemorrhagic conditions, or myocarditis/pericarditis was not higher in the vaccinated patients than in the unvaccinated patients. Guillain-Barre syndrome, Kawasaki disease/ MIS-C, and anaphylaxis or anaphylactic shock were not observed in any patient [26]. An important limitation of that study was that only severe adverse effects were screened with the help of the International Classification of Disease codes, and the effects of the vaccine, such as exacerbation of immune-mediated disease, progression of CKD stage, and rejection in transplant patients, were not evaluated.…”
Section: Discussionmentioning
confidence: 99%